RSAD2: A Potential Drug Target and Biomarker (G91543)

Target Name: RSAD2

NCBI ID: G91543

RSAD2

RSAD2: A Potential Drug Target and Biomarker

Introduction

Renal cancer is a leading cause of cancer-related mortality worldwide, with a rising trend in incidence in both humans and animals. The development of drug resistance and limited treatment options for renal cancer has made the search for new therapeutic targets of great clinical significance . In recent years, studies have found that RSAD2 (endoplasmic reticulum-associated, interferon-inducible) has potential clinical value in the treatment of kidney tumors. This article aims to explore the role of RSAD2 in the treatment of renal tumors and explore the possibility of RSAD2 as a drug target or biomarker.

Discovery and mechanism of action of RSAD2

RSAD2 is a protein with a molecular weight of 41.1 kDa and a member of the eukaryotic-derived cytokine (such as interferon) family 1 (IF1). RSAD2 is expressed in a variety of tumor cells, including kidney cancer, liver cancer, breast cancer, etc. Studies have found that RSAD2 is closely related to the growth, apoptosis and immune evasion of various tumor cells.

The role of RSAD2 in tumor cell growth

RSAD2 plays multiple roles in tumor cell growth. First, RSAD2 can inhibit the spindle formation of tumor cells, leading to cell cycle arrest and inhibited cell proliferation. Secondly, RSAD2 can regulate the cell cycle of tumor cells, increase the time of the intermediate phase of the cell cycle, and prolong the cell cycle. In addition, RSAD2 can also promote the apoptosis of tumor cells and increase tumor cell apoptosis by regulating intracellular apoptosis signaling pathways, such as the Bcl-2/Asp-Homeod95 (BAH) pathway.

The role of RSAD2 in tumor cell apoptosis

RSAD2 plays multiple roles in tumor cell apoptosis. First, RSAD2 can regulate intracellular apoptosis signaling pathways, such as the BAH pathway, and increase tumor cell apoptosis. Secondly, RSAD2 can inhibit DNA replication of tumor cells and lead to cell apoptosis. In addition, RSAD2 can also affect the growth and apoptosis of tumor cells by regulating the cell cycle.

The role of RSAD2 in tumor cell immune evasion

RSAD2 plays multiple roles in tumor cell immune evasion. First, RSAD2 can inhibit the expression of MHC class I molecules in tumor cells, thereby blocking the interaction between tumor cells and immune cells. Secondly, RSAD2 can inhibit the expression of PD-L1 in tumor cells, thereby reducing the interaction between tumor cells and immune cells. In addition, RSAD2 can also affect the expression of TIM-3 in tumor cells and further block the interaction between tumor cells and immune cells.

Application of RSAD2 in drug screening

The application of RSAD2 in drug screening is mainly reflected in two aspects: inhibiting tumor cell growth and promoting tumor cell apoptosis. First, research has found that RSAD2 has the effect of inhibiting tumor cell growth and can be used as a potential anti-tumor drug target. Secondly, RSAD2 can promote tumor cell apoptosis and can be used as a potential anti-tumor drug target.

RSAD2 as a potential drug target

RSAD2 has significant potential in drug screening and can serve as a potential anti-tumor drug target. First of all, RSAD2 can inhibit the growth of tumor cells, thereby blocking the proliferation of tumor cells, which has positive significance for tumor treatment. Secondly, RSAD2 can promote tumor cell apoptosis and can be used as an apoptosis therapeutic target for anti-tumor drugs. In addition, RSAD2 can also regulate the cell cycle of tumor cells, affect the growth and apoptosis of tumor cells, and has a wide range of anti-tumor effects.

Possibility of RSAD2 as a biomarker

RSAD2 has important biological significance in tumor research. First of all, RSAD2 can be used as a tumor biomarker for tumor diagnosis and prognosis. Secondly, RSAD2 can be used as a target for tumor treatment and has significant anti-tumor effects.

Biological significance of RSAD2

RSAD2 has important biological significance in tumor research. First of all, RSAD2 can be used as a tumor biomarker for tumor diagnosis and prognosis. For example, studies have found that RSAD2 expression is significantly related to the survival rate of kidney cancer patients and can be used as a prognostic factor for kidney cancer patients.

Protein Name: Radical S-adenosyl Methionine Domain Containing 2

Functions: Interferon-inducible antiviral protein which plays a major role in the cell antiviral state induced by type I and type II interferon (PubMed:31812350). Catalyzes the conversion of cytidine triphosphate (CTP) to 3'-deoxy-3',4'-didehydro-CTP (ddhCTP) via a SAM-dependent radical mechanism (PubMed:29925952, PubMed:30872404). In turn, ddhCTP acts as a chain terminator for the RNA-dependent RNA polymerases from multiple viruses and directly inhibits viral replication (PubMed:29925952). Therefore, inhibits a wide range of DNA and RNA viruses, including human cytomegalovirus (HCMV), hepatitis C virus (HCV), west Nile virus (WNV), dengue virus, sindbis virus, influenza A virus, sendai virus, vesicular stomatitis virus (VSV), zika virus, and human immunodeficiency virus (HIV-1) (PubMed:29925952, PubMed:30587778, PubMed:31921110, PubMed:30934824). Promotes also TLR7 and TLR9-dependent production of IFN-beta production in plasmacytoid dendritic cells (pDCs) by facilitating 'Lys-63'-linked ubiquitination of IRAK1 by TRAF6 (PubMed:30872404). Plays a role in CD4+ T-cells activation and differentiation. Facilitates T-cell receptor (TCR)-mediated GATA3 activation and optimal T-helper 2 (Th2) cytokine production by modulating NFKB1 and JUNB activities. Can inhibit secretion of soluble proteins

The "RSAD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RSAD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets